SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 2,700 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 2,700 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.85, for a total value of $13,095.00. Following the transaction, the insider directly owned 283,852 shares of the company’s stock, valued at $1,376,682.20. The trade was a 0.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $4.86 on Thursday. The business has a 50 day simple moving average of $4.77 and a two-hundred day simple moving average of $4.68. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The stock has a market capitalization of $332.86 million, a P/E ratio of -9.53 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The firm had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. As a group, analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC acquired a new stake in shares of SOPHiA GENETICS in the third quarter valued at approximately $6,708,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $2,009,000. Finally, 1492 Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $973,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5?1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
• Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5?1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
• Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5?1 plan; still owns ~204–205k shares. SEC filing
• Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5?1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
• Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre?arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of research analyst reports. Guggenheim increased their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research reissued a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.